BioXcel Therapeutics CSO Frank Yocca's Stock Transactions and RSU Vesting

This Form 4 filing reports stock transactions by Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics. On May 4, 2026, Yocca received 17,500 shares of common stock through the vesting of restricted stock units (RSUs) at $0 per share, increasing his direct holdings to 33,020 shares. The RSUs were part of a 70,000-unit grant from January 1, 2026, with vesting scheduled over two years. Subsequently, on May 20, 2026, Yocca sold 6,845 shares at a weighted average price of $1.085 per share, reducing his direct holdings to 26,175 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on February 3, 2026, specifically to cover taxes related to the RSU vesting. The filing also notes that Yocca continues to hold 52,500 unvested RSUs following these transactions.